Literature DB >> 7129409

The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity.

C R Abramowsky, G L Swinehart.   

Abstract

Patients with cystic fibrosis are chronically exposed to several potentially nephrotoxic factors. These include bacterial infections with their associated immune complexes and the antibiotics (aminoglycosides) used in their treatment. In addition, diabetes mellitus, liver disease, and cor pulmonale, commonly seen in these patients, may produce renal injury. To assess the extent of this injury, we performed morphologic and immunopathologic studies of the kidneys of 34 patients at autopsy. The group included 23 female and 11 male patients; their ages ranged from 4 months to 35 years and their disease was diagnosed one month to 22 years prior to death. The histological changes included glomerulomegaly, a mesangiopathic lesion, and tubulointerstitial disease frequently associated with acute and chronic tubular injury. The last was characterized by abundant tubular lysosomal proliferation and tubular atrophy suggestive of chronic amino-glycoside injury. Diagnostic diabetic lesions were not seen. Immunofluorescence studies predominantly revealed deposits of IgM or C3, or both, in glomeruli and arterioles in 18 patients. Although an anti-Pseudomonas antiserum did not show bacterial antigens in the tissues, elution studies in two specimens demonstrated antibacterial antibodies. These observations, coupled with the finding of ultrastructural glomerular deposits, suggest immune complex-mediated injury. No correlation was found between the severity or type of renal histologic lesion and patient age or duration of cystic fibrosis. Despite the occurrence of renal failure in six patients, renal involvement is currently of limited clinical concern in cystic fibrosis. Nevertheless, continued exposure to bacterial immune complexes and aminoglycosides, among other factors, can result in potentially serious renal disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7129409     DOI: 10.1016/s0046-8177(82)80056-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

Review 1.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  Cadmium regulates the expression of the CFTR chloride channel in human airway epithelial cells.

Authors:  Jessica Rennolds; Susie Butler; Kevin Maloney; Prosper N Boyaka; Ian C Davis; Daren L Knoell; Narasimham L Parinandi; Estelle Cormet-Boyaka
Journal:  Toxicol Sci       Date:  2010-04-02       Impact factor: 4.849

3.  Diuretic effect and disposition of furosemide in cystic fibrosis.

Authors:  J Prandota; I J Smith; B C Hilman; J T Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

5.  Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.

Authors:  S S Pedersen; T Jensen; D Osterhammel; P Osterhammel
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance.

Authors:  Yasmina Yahiaoui; Mathieu Jablonski; Dominique Hubert; Helen Mosnier-Pudar; Laure-Hélène Noël; Marc Stern; Dominique Grenet; Jean-Pierre Grünfeld; Dominique Chauveau; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

7.  Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy.

Authors:  G Steinkamp; M Lütge; U Wurster; J G Schulz-Baldes; H J Gröne; J H Ehrich
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

8.  Severe nephropathy in three adolescents with cystic fibrosis.

Authors:  M L Melzi; D Costantini; M Giani; A C Appiani; A M Giunta
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

Review 9.  Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Authors:  D J Morgan; K M Bray
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

10.  Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.

Authors:  A Omri; C Beaulac; M Bouhajib; S Montplaisir; M Sharkawi; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.